Qualitix is a full service CRO based in Taipei, Taiwan and Shanghai, China, and engaged in clinical monitoring and site management services for multinational clinical trials.
With this acquisition, QPS-Qualitix will have a range of product development, clinical research, and regulatory services in Taiwan.
QPS-Taiwan president and CEO Vincent Yen said this expansion in Phase I-IV clinical capability dovetails with their recent preclinical facility acquisition here in Taiwan.
" Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint," Yen said.